Author: Daniela Barros

Serum calcitonin levels shows more sensitivity than cytopathology for the medullary thyroid cancer diagnosis

In the present study, serum calcitonin levels were more sensitive than cytopathology for diagnosis of medullary thyroid cancer (MTC) and were able to identify all patients who could not be diagnosed by FNAB. Besides, Bethesda category III was more prevalent in the group of patients carrying this neoplasm. Read More →

The inclusion of BRAFV600E mutational status has a limited impact on risk stratification in papillary thyroid carcinoma

Although the prognostic role of BRAFV600E mutation in papillary thyroid carcinoma (PTC) is controversial, the American Thyroid Association (ATA) includes the mutational status in their risk stratification system. The present study aimed to evaluate the impact of the BRAFV600E mutation status on risk stratification as well as on disease outcomes in patients with PTC. Read More →

Computerized image analysis detected differences in chromatin in follicular lesions

The present study evaluated whether a computerized image analysis would be able to detect nuclear differences between three thyroid tumor subtypes (NIFTP, IEFVPTC, and IFVPTC). The results point to the possibility of showing differences in the nuclear texture between NIFTP (non-invasive follicular thyroid neoplasm) and IFVPTC (infiltrative follicular variant of papillary thyroid carcinoma), but not for IEFVPTC (tumour capsular invasion). Read More →

Prolonged use of bisphosphonates or drug holiday? Answers remain uncertain

An estimated 162 osteoporosis-related fractures are prevented for each atypical femoral fracture associated with an anti-resorptive medication. However, there are still controversies about the prolonged use of bisphosphonates. Researchers conducted a literature review in search of the best strategy. Read More →